Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Syndicated Research

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Vandria announces positive phase 1 data for Alzheimer’s treatment

    Trial data showed that VNA-318 has the ability to penetrate the brain

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

    Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

    - PMLiVE

    AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition

    The deal includes a candidate in phase 1 development for Alzheimer's disease

    - PMLiVE

    Making at Impact at the Alliance Industry Summit

    The Medscape team will be returning to the Alliance Industry Summit in Philadelphia this year, bringing with them Best in Class Outcomes and support for the event. As part of...

    Medscape Education

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug shows continued cognitive improvement in long-term study

    Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease

    - PMLiVE

    AI tool better predicts progress of Alzheimer’s versus current clinical tests

    The most common form of dementia accounts for up to 80% of all cases

    - PMLiVE

    Eli Lilly’s Alzheimer’s drug Kisunla granted FDA approval for early symptomatic disease

    The amyloid plaque-targeting therapy could result in lower treatment costs and fewer infusions

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links